Topic starter
A new double-blind, placebo-controlled crossover study conducted by the University of Basel has investigated what a MDMA booster dose exactly how it affects the duration and intensity of the experience, as well as any side effects.
The study has been published in Translational Psychiatry and is relevant because MDMA-assisted psychotherapy (MDMA-AT), which is being investigated as a treatment for conditions including post-traumatic stress disorder (PTSD), typically involves an initial dose followed by a "booster dose" 1.5 to 2.5 hours later.
However, until now, there has been very little systematic research into exactly what the booster dose achieves.
Study design
Twenty-five healthy volunteers took part, of whom 23 (12 men, 11 women) completed all the dosing sessions.
Three conditions were compared with one another in random order: 120 mg of MDMA followed by a booster dose of 60 mg after 2 hours, 120 mg of MDMA followed by a placebo after 2 hours, and placebo followed by placebo.
The primary outcome measure was the total duration of subjective effects, measured using a Visual Analogue Scale (VAS). In addition, other subjective effects, adverse effects, vital signs and plasma concentrations of MDMA, oxytocin and neurophysin I were measured.
Does the booster dose prolong the experience?
Yes: the 60 mg MDMA booster dose clearly prolonged the acute subjective effects, from an average of 4.6 hours (± 1.2 hours) without a booster to 5.6 hours (± 1.8 hours) with a booster (p = 0.001).
What stands out: there were no differences found in the peak intensity of the subjective or autonomic (physical) effects between the two conditions.
So the booster dose makes the experience, above all, longer, not necessarily more intense at its peak.
Side effects
Both acute side effects (within the first 9 hours) and subacute side effects (up to 3 days later) were more common after both MDMA conditions compared with placebo.
However, the study does not explicitly state whether the booster dose also led to more side effects than the single dose; the main comparison reported by the researchers is that between MDMA (with or without a booster) and placebo.
Conclusion
These results show that the acute effects of MDMA can be prolonged with a booster dose, exactly as intended in clinical MDMA-AT trials.
However, the researchers strongly emphasise that further research is needed to determine whether this prolonged duration of action actually translates into a better clinical outcome for patients, for example in the treatment of PTSD.
In other words: a longer course of treatment has been demonstrated, but whether this also results in better treatment is a separate question that requires further research.
Addition
This research is of practical relevance to anyone familiar with the protocol for MDMA-assisted therapy, such as that used, for example, in the MAPS trials for PTSD: in these trials, a booster dose is routinely administered, usually around half the initial dose, approximately 1.5 to 2.5 hours after the first dose.
This study now provides, for the first time, hard data to substantiate exactly what the booster does: not a higher peak, but a a longer, stable plateau about an extra hour.
In therapeutic settings, this can be valuable, as a longer, more stable plateau may allow more scope to work through deeper-seated issues without the session "levelling off" prematurely.
At the same time, the finding that side effects occurred more frequently following MDMA than following placebo once again underlines that a booster dose is not a trivial addition: close monitoring of vital signs and well-being remains essential, even though this study was conducted on healthy volunteers in a strictly controlled clinical setting.
Posted : 13 September 2026 09:58